Targeted Analysis of Whole Genome Sequence Data to Diagnose Genetic Cardiomyopathy

Abstract

Background Cardiomyopathy is highly heritable but genetically diverse. At present, genetic testing for cardiomyopathy uses targeted sequencing to simultaneously assess the coding regions of more than 50 genes. New genes are routinely added to panels to improve the diagnostic yield. With the anticipated $1000 genome, it is expected that genetic testing will shift towards comprehensive genome sequencing accompanied by targeted gene analysis. Therefore, we assessed the reliability of whole genome sequencing and targeted analysis to identify cardiomyopathy variants in 11 subjects with cardiomyopathy. Methods and Results Whole genome sequencing with an average of 37× coverage was combined with targeted analysis focused on 204 genes linked to cardiomyopathy. Genetic variants were scored using multiple prediction algorithms combined with frequency data from public databases. This pipeline yielded 1-14 potentially pathogenic variants per individual. Variants were further analyzed using clinical criteria and/or segregation analysis. Three of three previously identified primary mutations were detected by this analysis. In six subjects for whom the primary mutation was previously unknown, we identified mutations that segregated with disease, had clinical correlates, and/or had additional pathological correlation to provide evidence for causality. For two subjects with previously known primary mutations, we identified additional variants that may act as modifiers of disease severity. In total, we identified the likely pathological mutation in 9 of 11 (82%) subjects. Conclusions These pilot data demonstrate that ~30-40× coverage whole genome sequencing combined with targeted analysis is feasible and sensitive to identify rare variants in cardiomyopathy-associated genes.

Whole Genome Sequence Identified a Rare Homozygous Pathogenic Mutation of the DSG2 Gene in a Familial Arrhythmogenic Cardiomyopathy Involving Both Ventricles

“…We then identified 151 missense SNP of exons and 2 of splicing mutations. Using screening methods described in a previous study [9], we filtered these against the 1000 Genomes Project database, the NHLBI ESP6500 database, and ExAC with allele frequencies ≥0.01. We identified 12 missense mutations of exons (Table 3), the allele frequencies of which were <0.01 or unknown.…”

Reassessment of Mendelian gene pathogenicity using 7,855 cardiomyopathy cases and 60,706 reference samples

“…LOD >3) and here the possibility exists that the reported disease association is entirely spurious. An argument is often made that variants in candidate genes, even if not causal, could be contributing as modifiers (43,44). This remains possible but in the absence of any significant over-representation in cases the more parsimonious interpretation is that they are phenotypically silent.…”

A Comparison of Whole Genome Sequencing to Multigene Panel Testing in Hypertrophic Cardiomyopathy Patients

“…Two patients (7.1%) had novel candidate genes identified. Golbus et al 42 performed WGS in 11 individuals with nonischemic DCM. WGS confirmed a previously identified variant in 3 subjects, identified possible new causal variants in 6 subjects, was negative in 2 subjects, and identified potential disease modifiers in two families exhibiting variable disease expression.…”